ResearcherUniversity of TorontoNo recent work listed
Sarah B. Bateni
Matched on ORCID iD 0000-0002-9175-0733; OpenAlex author ID A5065807399. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper
Papers 3
- Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surgery. First author DOI 10.1001/jamasurg.2022.2590↗
- Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? First author DOI 10.1016/j.jamcollsurg.2021.02.014↗
- Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2019.3019↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Richard J. Bold · 3 shared papers, 2019–2022 · strength 0.49
- Paper Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? DOI 10.1016/j.jamcollsurg.2021.02.014↗
- Paper Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surger… DOI 10.1001/jamasurg.2022.2590↗
- Paper Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. DOI 10.1001/jamasurg.2019.3019↗
- Lauren M. Perry · 2 shared papers, 2021–2022 · strength 0.37
- Paper Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers? DOI 10.1016/j.jamcollsurg.2021.02.014↗
- Paper Evaluation of Adherence to Venous Thromboembolism Prophylaxis Guidelines Among US Adults After Pancreatic Cancer Surger… DOI 10.1001/jamasurg.2022.2590↗
- Jeffrey S. Hoch · 2 shared papers, 2019–2021 · strength 0.32
- Robert J. Canter · 2 shared papers, 2019–2022 · strength 0.30
- Julie I. Hallet · 1 shared paper, 2022 · strength 0.17
- Sepideh Gholami · 1 shared paper, 2022 · strength 0.17
- Ryan P. Merkow · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.